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Objective. Acute pain management in opioid dependent persons is complicated 
because of tolerance and opioid-induced-hyperalgesia. Very high doses of morphine 
are ineffective in overcoming opioid-induced-hyperalgesia and providing 
antinociception to methadone maintained patients in an experimental setting. 
Whether the same occurs in buprenorphine maintained subjects is unknown. 
 
Design. Randomised double blind placebo controlled. Subjects were tested on two 
occasions, at least five days apart; once with intravenous morphine and once with 





Subjects. Twelve buprenorphine maintained subjects: once daily sublingual dose 
(range 2-22 mg); no dose change for 1.5-12 months. Ten healthy controls.  
 
Methods. Intravenous morphine bolus and infusions administered over 2 hours to 
achieve two separate pseudo-steady state plasma concentrations one hour apart. 
Pain tolerance assessed by application of nociceptive stimuli (cold pressor (seconds) 
and electrical stimulation (volts)). Ten blood samples collected for assay of plasma 
morphine, buprenorphine and norbuprenorphine concentrations until 3 hours after 
the end of last infusion; pain tolerance and respiration rate measured to coincide with 
blood sampling times. 
 
Results. Cold pressor responses (seconds): baseline: control 34±6 versus 
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buprenorphine 17±2 (P=0.009); morphine infusion-end: control 52±11(P=0.04), 
buprenorphine 17±2 (P>0.5); electrical stimulation responses (volts): baseline: 
control 65±6 versus buprenorphine 53±5 (P=0.13); infusion-end: control 74±5 
(P=0.007), buprenorphine 53±5 (P>0.98). Respiratory rate (breaths per minute): 
baseline: control 17 versus buprenorphine 14 (P=0.03); infusion-end: control 15 
(P=0.09), buprenorphine 12 (P<0.01). Infusion-end plasma morphine concentrations 
(ng/mL): control 23±1, buprenorphine 136±10. 
 
Conclusions. Buprenorphine subjects, compared with controls, were: hyperalgesic 
(cold pressor test); did not experience antinociception, despite high plasma morphine 
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The prevalence of opioid dependence is growing worldwide. Dependence has 
traditionally been the result of illicit opioid abuse. However, it is increasingly 
associated with legally prescribed long-term use of opioids for the management of 
chronic pain [1]. Between 28 and 38.5 million people abuse opioids worldwide. In 
2015, 2 million had a substance use disorder involving prescription pain relievers 
and 591,000 had a substance use disorder involving heroin [2]. Approximately 1% of 
the Australian population is opioid dependent and half of these are in opioid 
substitution treatment (OST) programs [3]. Of these, two-thirds receive methadone 
and one third buprenorphine (alone or with naloxone) but this difference is declining. 
 
The management of acute pain in opioid dependent patients is complicated 
because of two major factors: tolerance, which can generally be overcome by dose 
increase but may be compromised by adverse effects, and the under recognized 
phenomenon of opioid-induced-hyperalgesia (OIH) characterized as paradoxical 
pain sensitization [4] which cannot be overcome by dose increase. Although there 
are no formal guidelines for the clinician, Macintyre et al [5] and Huxtable et al [6] 
advise, that in the clinical setting, the daily OST dose should be maintained and 
additional opioid used for acute pain management, titrated until satisfactory 
analgesia is achieved or an adverse effect (e.g. sedation or respiratory depression) 
occurs. Such an approach requires stringent observation such as admission to 
hospital. 
 
Opioid-induced hyperalgesia occurs in opioid (e.g. heroin) addicted subjects prior to 
entry into methadone and buprenorphine treatments [7], chronic non-cancer pain 
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patients [8], and slow release morphine, methadone and buprenorphine maintained 
subjects [9, 10, 11, 12]. Clinically used and very high doses of morphine are 
ineffective in overcoming OIH and providing antinociception to methadone 
maintained patients [11, 13] in an experimental setting. Whether the same occurs in 
buprenorphine maintained subjects is unknown. 
 
Buprenorphine, a semi-synthetic 4,5-epoxymorphinan opioid shows partial agonist 
properties for some responses at the mu opioid receptor and variable effects at 
the kappa and delta receptors [14]. Its major metabolite norbuprenorphine is also 
active [15], although there is conjecture whether it crosses the blood-brain barrier 
[16]. Opioid agonists such as morphine, over plasma concentration ranges that 
produce dose-related increases in analgesia, also produce concentration-
dependent respiratory depression without any plateau in healthy human 
volunteers [17]. In contrast, buprenorphine shows dose-dependent increases in 
analgesia with a limited extent of respiratory depression [17, 18]. As a partial 
agonist, under appropriate conditions, buprenorphine may act as an agonist or 
antagonist at opioid receptors [19] and has shown antihyperalgesic effects in 
healthy subjects using a model of intradermal electric stimulation [20]. Therefore, 
buprenorphine may be unique in its ability to treat acute pain and possibly 
attenuate OIH. 
 
Previously we showed that methadone maintained subjects on doses of 2-120 mg 
per day, under identical experimental conditions that will be described in this study, 
experienced no antinociception with 55 mg of intravenous morphine but showed a 
significant reduction in respiratory rate [13]. To date, no studies have examined the 
effect of different daily buprenorphine doses on the antinociceptive and respiratory 
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responses to morphine. 
 
The aims of the study in buprenorphine maintained subjects were to: 1. Confirm the 
presence of OIH; 2. Ascertain whether very high intravenous morphine doses 
produce antinociceptive and respiratory depression effects and 3. Determine any 
relationship between buprenorphine dose and these effects. Our hypothesis is that 
buprenorphine maintained subjects are hyperalgesic and, that in contrast to 





The Research Ethics Committee of the Royal Adelaide Hospital, Adelaide, South 
Australia, Australia (RAH Protocol no: 010222) and the Institutional Review Board, 
Friends Research Institute, Los Angeles, California, USA (FRI IRB no: 00-03-057-
02) approved the study. Both bodies adhere to the ethical standards set by the 
Helsinki Declaration (2008). The study was supported by National Institutes of Drug 
Abuse (NIDA) grant R01 DA 13706-02. This study was not registered on 
clinicaltrials.gov as this study was carried out before the requirement for 
registration. Subjects provided written informed consent, were paid for their 
involvement in the study and were free to withdraw at any time. 
 
Subjects 
Twelve buprenorphine maintained subjects comprising 7 men and 5 women with 
ages between 24 and 42 years (mean 35 years) were recruited. Their weights 
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ranged between 49 and 97 kg (mean 71 kg). They had been receiving sublingual 
buprenorphine (Subutex ® Reckitt Benckiser, West Ryde, New South Wales, 
Australia) for between 1.5 and 12 months (mean 4 months) with no dose change. 
They had been enrolled in a buprenorphine maintenance program for a period 
ranging between 2 and 22 months with a mean of 10 months. The group was 
stratified according to dose, with four subjects in each of the dose ranges of 2 to 8 
mg, 9 to 15 mg and 16 to 22 mg per day. Subjects were recruited if they self-
reported intravenous heroin use at least once in the previous month. It was 
considered more ethical to administer morphine to individuals who continued to use 
illicit heroin, rather than to those who used no opioids, apart from their prescribed 
buprenorphine. Ten healthy control subjects (5 men and 5 women; aged between 
21 and 41(mean 31) years); weight 59 and 102 (mean 80) kg) were selected. 
These subjects were not taking any prescribed medications. They have been 




Exclusion criteria for all subjects included pregnancy or lactation, use of 
antiretroviral drugs, significant medical or psychiatric illness that required ongoing 
treatment (except opioid addiction for buprenorphine subjects), daily alcohol 
consumption exceeding 40 g for men and 20 g for women, severe liver impairment 
(serum aspartate aminotransferase and alanine aminotransferase concentrations 
greater than 3 times the upper limit of normal range and albumin concentrations 
less than 33 grams per litre) or haemoglobin counts outside the normal range. 
Healthy control subjects were excluded if they had any personal or family history of 
Page 7 of 92





































































The study utilized a double blind placebo controlled design with four groups of 
subjects (healthy controls, once daily buprenorphine dose of 2 to 8, 9 to 15 and, 
16 to 22 mg). Subjects were tested on two occasions, at least five days apart; 
once with morphine and once with saline. The order of administration was 
randomised. Buprenorphine subjects were tested at about the time of putative 
trough plasma concentrations of buprenorphine (approximately 20 hours after 
the previous buprenorphine dose). 
Procedure 
Subjects were asked not to use any analgesics or illicit substances for twenty-four 
hours prior to testing. A urine sample was collected on each study day for the 
detection of opioids, benzodiazepines, sympathomimetic amines, cannabinoids and 
barbiturates. Analysis of these samples confirmed that control subjects had not taken 
any of these psychoactive substances. Subjects were excluded from the study if they 
presented on study or screening days showing any signs of intoxication from any 
substance. 
 
Testing was conducted under constant ambient temperature (24LC) and constant 
illumination (70 lux). Each session commenced at approximately 8 am and lasted 8 
hours. Two indwelling catheters (Insyte Autoguard, Becton Dickenson, Sandy, Utah, 
USA) were inserted into peripheral veins on opposite arms. The catheter in the 
dominant arm served for drug infusion; the catheter in the non-dominant arm for 
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blood sampling. On each testing day, saline was infused at 2 ml/min for 30 min prior 
to morphine or saline administration for familiarisation. 
 
Morphine administration 
Morphine sulphate (David Bull Laboratories, Melbourne, Australia) infusions of 1 
mg/ml were administered intravenously in two sixty-minute stages to achieve two 
consecutive target pseudo-steady-state plasma concentrations [11] using a 
syringe driver infusion pump (3100 Graseby Syringe Pump, Watford, Hertfordshire, 
UK). Buprenorphine subjects received an initial bolus of 15.2 mg of morphine 
sulphate followed by a constant infusion of 8.3 mg/hr for one hour to achieve a 
target pseudo steady-state plasma concentration of 80 ng/ml (Morphine 1). They 
were then administered an additional bolus of 15.2 mg of morphine sulphate 
followed by a constant infusion of 16.5 mg/hr for one hour to achieve the second 
target pseudo steady-state plasma concentration of 180 ng/ml (Morphine 2). The 
prescribed buprenorphine dose was administered 1 hour after infusions ceased. 
Control subjects were administered an initial bolus of 2.2 mg morphine sulphate 
followed by a constant infusion of 1.2 mg/hr for one hour to achieve a target 
pseudo steady-state plasma concentration of 11 ng/ml (Morphine 1). They were 
then administered 4.95 mg of morphine sulphate followed by a constant infusion of 
3.6 mg/hr to achieve the second target pseudo steady-state plasma concentration 
of 33 ng/ml (Morphine 2) [11]. 
 
Blood sampling and assessment times  
Seven millilitre blood samples were taken at the following times: prior to the thirty 
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minute saline familiarisation infusion, ten minutes prior to end of this infusion 
(designated as baseline) and ten minutes prior to the end of each of the two 
morphine or placebo saline infusions. Further blood samples were taken at 0.25, 
0.5, 0.75, 1.0, 2.0, and 3 hours after the end of the last infusion. The blood samples 
were centrifuged immediately and the plasma stored at –20 LC until assay. 
Respiration rate was measured and nociceptive tests (see below) were 
administered immediately after the collection of each blood sample except at 0.25, 
0.50 and 0.75 hours after the last infusion. 
 
Nociceptive tests, physiological responses and safety monitoring 
Two nociceptive tests were administered: the cold pressor using the non-dominant 
arm, and electrical stimulation using the earlobe. These tests have been described 
previously [10]. Cold pressor involves the immersion of the non-dominant arm in 
0.5–1.5 LC water and the response metric is seconds. Electrical stimulation 
involves the transmission of an electrical pulse through the earlobe and is 
measured in volts. One nociceptive marker was used which was pain tolerance, 
when the participant verbally indicated that they could no longer tolerate the pain 
and removed their arm from the water or requested that the electrical stimulation 
cease. 
 
Respiration rate was measured over one minute by observation without the 
subjects’ awareness. Safety was monitored and recorded throughout the study 
by means of continuous pulse oximetry, continuous ECG waveform, categorical 
nausea scale [21] and categorical sedation scale [22]. 
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Plasma opioid quantification 
The quantification of plasma buprenorphine and norbuprenorphine was by high 
performance liquid chromatography coupled to mass spectrometry as previously 
described [23]. The assay had a limit of quantification of 0.125 ng/ml for both 
analytes and all variability in accuracies and precision had coefficients of variation 
for buprenorphine and nor-buprenorphine of less than 15%. The quantification of 
plasma morphine was by high-performance liquid chromatography (HPLC) with 
coulometric detection as previously described [11]. The assay had a lower limit of 
quantification of 1 ng/ml and all variability in accuracies and precision had 
coefficients of variation below 7%. 
 
Data analysis 
Data are presented as mean ± SEM (with 95% confidence intervals (95% CI)). 
One-way ANOVA was used to compare outcome variables (cold pressor 
tolerance, electrical stimulation tolerance, respiration rate) between the 
buprenorphine dose groups. One-way ANOVA was also used to compare each 
outcome variable across treatments for the buprenorphine dose groups, combined 
buprenorphine subjects and the control subjects with 95% CI of differences. 
Unpaired samples t-tests were used to compare baseline values between the 
combined buprenorphine subjects and the control subjects. The Pearson product-
moment correlation coefficient (Pearson’s r) was used to measure the linear 
correlation between individual buprenorphine daily doses and plasma morphine 
concentrations. Bonferroni’s and Dunnet’s tests were used for post-hoc analyses 
as appropriate. Data for both studies were analysed using GraphPad Prism 4.2 for 
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Windows, GraphPad Software, San Diego, California, USA and P<0.05 was 




There were no significant differences (P>0.45) in pain tolerance responses between 
the three buprenorphine dose groups from baseline to morphine infusion 1 or 
morphine infusion 2. Hence, the data from the groups were combined.  
 
Cold pressor responses 
Pain tolerance responses at baseline and morphine infusion 2 for control subjects 
and the buprenorphine subjects are shown in Figure 1 (upper panel) and absolute 
values and ranges for all treatments in Table 1. Pain tolerance values for the 
buprenorphine subjects remained unchanged between baseline and the two 
morphine infusions. Pain tolerance values for the buprenorphine subjects were 
significantly lower than for control subjects at baseline (ANOVA P=0.009; 95% CI -
5 to -30). Within group comparisons revealed that pain tolerance values for control 
subjects increased significantly (P=0.04) from baseline to morphine infusion 2 
(P<0.05; 95% CI 2 to 34), but not baseline to morphine infusion 1 (P>0.05; 95% CI 
-12 to 20).  
 
Electrical stimulation responses 
Pain tolerance responses at baseline and morphine infusion 2 for control subjects 
and the buprenorphine subjects are shown in Figure 1 (middle panel) and absolute 
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values with ranges given in Table 1. Pain tolerance values for the buprenorphine 
subjects were not significantly different to controls (ANOVA P=0.13) at baseline. 
Within-group comparisons revealed that pain tolerance values for control subjects 
increased significantly (P=0.007) from baseline to morphine infusion 2 (P<0.01; 
95% CI 3 to 16), but not baseline to morphine infusion 1 (P>0.05; 95% CI -2.8 to 
10). There was no significant change (P=0.98) in pain tolerance values for 
combined buprenorphine subjects from baseline to morphine infusion 1 or 
morphine infusion 2.  
 
Respiration rates 
Respiration rates (breaths per minute) relative to baseline and morphine infusion 2 
are shown in Figure 1 (lower panel) and absolute values with ranges in Table 1. 
Respiration rates for the buprenorphine subjects were significantly lower than for 
control subjects at baseline (ANOVA P=0.03; 95% CI -0.25 to -4.9). Within group 
comparisons revealed that the respiration rates for control subjects did not decrease 
significantly (P=0.09) from baseline to morphine infusion 1 or morphine infusion 2. 
Respiration rates for the buprenorphine subjects decreased significantly (ANOVA 
P=0.006) from baseline to morphine infusion 2 (P<0.01; 95% CI -0.9 to -4.4) but not 
morphine infusion 1 (P>0.05; 95% CI -2.8 to 10). 
 
Buprenorphine dose group comparisons demonstrated significant changes in 
respiration rates as follows. Group 2-8 mg daily: (ANOVA P=0.024) from baseline to 
morphine infusion 1 (P<0.05; 95% CI -0.56 to -7.4) and baseline to morphine 
infusion 2 (P<0.05; 95% CI -0.56 to - 7.4); group 9-15 mg daily: (ANOVA P=0.004) 
between baseline and morphine infusion 2 (P<0.01; 95% CI –1.48 to-5.52), but not 
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morphine infusion 1 (P>0.05; 95% CI -2.02 to 2.02); group 16 to 22 mg daily: 
(ANOVA P=0.016) between both baseline and morphine infusion 1 (P<0.05; 95% CI 
-0.72 to -4.28) and baseline and morphine infusion 2 (P<0.05; 95% CI -0.22 to -
3.78). There were no significant differences in respiration rate between the groups 
at baseline (P=0.90) or morphine infusion 2 (P=0.67). The lowest recorded 
respiration rates were ten breaths per minute in the control group and nine breaths 
per minute in the buprenorphine subjects. 
 
Adverse events 
There were no serious adverse events. Buprenorphine subjects did not experience 
nausea or vomiting, but seven control subjects required one dose of intramuscular 
metoclopramide hydrochloride 10 mg (Pfizer, Perth, Australia) with good effect for 
mild vomiting. 
 
Plasma morphine, buprenorphine and norbuprenorphine concentrations  
Pseudo steady-state plasma morphine concentrations for morphine 1 and 2 
infusions are shown in Table 2A. Target pseudo steady-state plasma morphine 
concentration for the buprenorphine recipients were 80 ng/ml (Morphine 1) and 180 
mg/ml (Morphine 2). Target pseudo steady-state plasma concentration for control 
subjects were 11 ng/ml (Morphine 1) and 33 mg/ml (Morphine 2). Pseudo state 
plasma morphine concentrations were lower than the desired target in both groups 
at morphine 1 and 2. Plasma morphine concentrations are also shown for the 
individual daily buprenorphine dose groups 2-8, 9-15 and 16-22 mg/day. There was 
no significant correlation (p=0.08) between individual buprenorphine doses and 
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plasma morphine concentrations at morphine infusion 1. However, there was a 
significant inverse relationship between individual buprenorphine doses and plasma 
morphine concentrations at morphine infusion 2 (Pearson’s r =-0.74, p=0.006; slope 
95% CI - 0.92 to -0.28).   
 
There were no significant differences between combined mean plasma 
buprenorphine concentrations (Table 2B), or for the three dose groups, at baseline 
(P=0.64), morphine infusion 1 (P=0.71) or morphine infusion 2 (P=0.51).  Likewise, 
there were no significant differences between combined mean plasma 
norbuprenorphine concentrations (Table 2C), or for the three dose groups, at 
baseline, morphine infusion 1 or morphine infusion 2. At baseline on the saline 
administration day, plasma buprenorphine and norbuprenorphine concentrations 
were correlated to the buprenorphine dose (r2=0.36 and 0.58, respectively; 




To our knowledge, this is the first study to have examined the effect of added 
morphine to buprenorphine OST subjects who were pain-free at the time of study, 
using an experiment pain model. Buprenorphine subjects were hyperalgesic in the 
cold pressor test in comparison with controls. Very high doses of morphine (55 mg) 
produced high plasma concentrations (92 to 201 ng/ml) that failed to provide 
antinociception in either the electrical stimulation or cold pressor tests, irrespective 
of maintenance buprenorphine dose. In contrast, in control subjects, considerably 
lower morphine doses (12 mg), achieving much lower concentrations (19 to 32 
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ng/ml), provided antinociception in both tests. 
Our choice of using the cold pressor response to study opioid induced- 
hyperalgesia has been validated by others. Compton et al [13] examined 
hyperalgesia in opioid dependent subjects and found that these subjects, prior to 
induction and following stabilisation on either methadone or buprenorphine, were 
similarly hyperalgesic in the cold pressor test and did not exhibit hyperalgesia in the 
electrical stimulation test. Krishnan et al [12] compared the detection of 
hyperalgesia in opioid-substitution subjects maintained either on methadone or 
buprenorphine and healthy controls using the following pain stimuli: cold pain, 
electrical stimulation, mechanical pressure, and ischemic pain. They found that cold 
pain was the most suitable of the methods tested to detect opioid-induced 
hyperalgesia. 
 
While the buprenorphine maintained subjects were tolerant to the antinociceptive 
effects of the high doses of morphine and plasma concentrations to which they 
were exposed, complete cross-tolerance to the respiratory depressant effects of 
morphine did not occur. Respiration rates dropped significantly across all dose 
groups, but by a limited amount (approximately 1.5 breaths per minute), which may 
not be clinically significant. In healthy volunteer subjects who received a single 
intravenous dose (0.2 mg/kg) of morphine, over a plasma concentration range 
(approximating 3-13 ng/mL) that produced a systematic increase in analgesia, 
morphine produced significant respiratory depression [24]. In contrast, in healthy 
adult volunteers who had experience with opioids but who were not physically 
dependent on opioids, Walsh and co-workers [18] demonstrated that respiratory 
depression increased with single buprenorphine single doses over a range of 1 to 4 
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mg (approximately 4 breaths per minute decrease), but that this dose effect began 
to plateau at higher doses, with no difference between a 16 and 32 mg dose. In the 
present study, with subjects chronically maintained on buprenorphine, high doses 
of added morphine had a limited respiratory depressant effect at all buprenorphine 
doses. It is, however, possible that higher doses of morphine might produce 
respiratory depression if such doses are needed to achieve anti-nociception, given 
that the lowest respiratory rate recorded was nine breaths per minute. Macintyre et 
al [25] showed increased sedation score (a surrogate for respiratory depression) in 
buprenorphine-maintained patients who received higher doses of morphine 
equivalents following surgery than in this study.  
 
Hyperalgesia is likely to be present, to a lesser or greater degree, in opioid 
recipients for whatever indication. Non-cancer pain patients, maintained on either 
methadone or slow release oral morphine for the treatment of that pain, were 
shown to exhibit hyperalgesia in the cold pressor test [8], similar to that seen in 
methadone [13] and buprenorphine subjects (this study) in opioid substitution 
programs. Chakrabarti et al [26] (2010) found that people with a greater reported 
experience of pain prior to induction onto buprenorphine maintenance required 
greater daily doses. The present study found that there was no difference in the 
degree of hyperalgesia experienced at baseline between the three dose ranges. 
There was also no difference between the three dose ranges in terms of cross-
tolerance to the antinociceptive effects of very high dose morphine. 
 
The most widely used drugs in opioid substitution programmes worldwide are 
methadone and buprenorphine, with the latter gaining increasing prominence. 
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Methadone maintained subjects were examined under conditions identical [13] to 
those for the buprenorphine subjects in this study. The cold pressor test at 
baseline revealed that the combined methadone subjects were similarly 
hyperalgesic to the combined buprenorphine subjects. Furthermore, both groups 
were cross-tolerant to the antinociceptive effects of very high plasma morphine 
concentrations and both groups experienced similar decreases in respiration rate 
with the addition of very high plasma morphine concentrations. While 
buprenorphine has been used increasingly across the world because of its 
purported limited effect on respiratory depression and greater safety profile than 
other opioids such as morphine and methadone [17, 27, 28], our findings suggest 
that supplementary opioids for the management of pain in subjects in opioid 
substitution programs should be added cautiously under adequate supervision to 
avoid clinically significant respiratory depression. 
 
Koppert et al [20], in a mechanical hyperalgesia model found that acutely, 
buprenorphine had a pronounced antihyperalgesic effect and suggested this may 
have clinical advantages in the management of chronic pain. In observational 
studies of chronic pain patients who were switched from high dose full opioid 
agonists to sublingual buprenorphine, [29, 30], the switch resulted in meaningful 
reduction in pain scores. Buprenorphine was more effective than full opioid 
agonists. The authors postulated that these findings may have resulted from 
buprenorphine’s antihyperalgesic action [29]. However, Ravn and coworkers [31], 
using a multimodal testing technique, could not demonstrate any significant 
differences between morphine and buprenorphine in the profiles of 
antihyperalgesia and analgesia in healthy volunteers. The present study shows 
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that buprenorphine, a partial mu opioid receptor agonist and kappa receptor 
antagonist, when used as a maintenance agent, produces similar respiratory 
depression and hyperalgesia to methadone (a mu opioid receptor agonist) in 
opioid maintained subjects tested under the same experimental conditions [13]. 
These results suggest that, at the buprenorphine doses to which our subjects 
were exposed, antihyperalgesia could not be demonstrated with the cold pressor 
test. 
 
Macintyre and colleagues [25] examined retrospectively pain relief and opioid 
requirements in the first 24 hours after surgery in patients taking buprenorphine 
(dose range was similar to that in the present study) and methadone as OST. 
Outcomes in the two patient groups were similar. The post-operative 24-hour 
analgesia requirement, provided as patient controlled analgesia, was defined as 
morphine dose equivalents. Buprenorphine maintained patients required an 
average of 200 mg; methadone maintained patients required 221 mg. Pain 
scores were similar across both groups. Sedation scores of 2 or greater occurred 
in 22.7% and 24.1% of buprenorphine and methadone maintained patients 
respectively. This important clinical study was not designed to determine 
possible mechanisms for the outcomes. Our findings, in an experimental setting 
in OST pain-free patients, complement the findings of this clinical study: very 
large morphine equivalent doses result in insignificant analgesia and the 
development of respiratory depression, albeit small, given the relatively small 
(compared to the PCA doses in the clinical study) dose of morphine provided to 
our subjects. Our findings strongly suggest that hyperalgesia is a likely 
mechanism for the findings of Macintyre and colleagues [25], in addition to 
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tolerance. It is pertinent that buprenorphine and methadone maintained patients 
behaved almost identically, suggesting that buprenorphine had no 
antihyperalgesic properties.  
 
We measured plasma concentrations of morphine, buprenorphine and 
norbuprenorphine to more accurately assess the extent of exposure by the 
subject to these analytes, rather than relying simply on the given doses. While 
there were no significant differences between plasma buprenorphine 
concentrations for the three dose groups at baseline, there was considerable 
variability in the range of concentrations. Hyperalgesia occurred across the 
whole range of plasma concentrations. The lowest individual plasma 
buprenorphine concentration was 0.16 ng/ml (in the 2-8 mg/day dose group).  
 
Transdermal buprenorphine patches are increasingly used for the management 
of chronic pain. In Australia, they are available in various strengths, ranging from 
10-40 mg, which deliver 10 to 40 ug/h and are generally applied once a week, 
likely for prolonged periods. When 10 ug/h patches were administered to healthy 
volunteers once a week for 3 doses the average plasma concentrations were 
between 0.155 and 0.172 ng/ml across the 3 periods [32]; 20 ug/h patches 
administered to healthy volunteers as a single dose yielded mean maximum 
plateau plasma concentrations of about 0.25 ng/ml between 48 and 96 hours 
after application [33]; single applications of 35 and 70 ug/h patches yielded mean 
maximum plasma concentrations of 0.31 and 0.62 ng/ml respectively [34]. These 
values fall within the range of plasma concentrations described in the present 
study that were associated with hyperalgesia. Thus, it would be reasonable to 
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assume that some patients receiving buprenorphine for the management of 
chronic pain could be hyperalgesic. Kress [34] reviewed several trials/reports of 
the efficacy of transdermal buprenorphine (varying doses) in patients with cancer 
and noncancer pain with the minimum duration of observation of three months. In 
most of the studies, satisfactory pain relief occurred in at least 50% of subjects, 
suggesting that hyperalgesia may not be universal in patients suffering from pain 
rather than those who receive opioids as substitution treatment.  
 
There are several limitations to this study. The sample size is small and not driven 
by a formal power calculation. However, we based our population size on the 
results of Doverty et al [11], who showed highly significant differences in cold 
pressor tolerance between 16 healthy controls (n=16) and 16 methadone 
maintenance subjects.  Despite the smaller sample size in this study, significant 
differences were seen between buprenorphine recipients and the controls. Plasma 
buprenorphine concentrations were measured only at the putative peak. However, 
given the long half-life of buprenorphine and that the subjects would have been at 
steady state, we considered the sampling regimen justified.  
 
What might be the best strategy to improve pain relief in buprenorphine maintained 
patients who experience acute pain, such as following surgery or trauma? Reviews 
from Huxtable et al [6] and Schug et al [5] state that in the clinical setting, for the 
opioid maintained population, opioid dose should be increased until analgesia is 
achieved or sedation occurs and that the dose of the maintenance opioid should be 
continued without interruption [25]. The purpose of this study was to provide the 
evidence for opioid dose escalation that would provide antinociception without 
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respiratory depression in the buprenorphine maintained population. This study 
demonstrates that buprenorphine maintained subjects are hyperalgesic at baseline 
and that very high morphine doses result in limited respiratory depression, but not 
antinociception. There is a need to explore alternative strategies for providing acute 
pain relief in buprenorphine (and methadone) maintained patients. For example, 
Huxtable [6] and Schug et al [5] recommend that an adjuvant analgesic alone, or in 
combination with morphine, may overcome the limitations of cross-tolerance and 
side effects to provide pain management in the buprenorphine and methadone 
maintained population. 
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Figure 1. Cold pressor pain tolerance responses (upper panel), electrical stimulation 
pain tolerance responses (middle panel) and respiration rate (lower panel) mean (± 
SEM) pain in 10 healthy control and 12 buprenorphine subjects at baseline (B) and 
morphine infusion 2 (M2). † P<0.05; †† P<0.01 between groups; * P<0.05; ** P<0.01 
between treatments. Note: different morphine concentrations between buprenorphine 
and control subjects. 
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Table 1. Cold pressor and electrical stimulation responses, and respiration rates for 12 
buprenorphine maintained and 10 control subjects on morphine administration days. 








(4 to 73) 
38±7 
(5 to 64) 
52±11*  






(9 to 18)  
17±2 
(4 to 29) 
17±2 




Control 65±6  
(38 to 100) 
68±5  
(48 to 100) 
74±5** 






(24 to 92) 
53±4 
(24 to 72) 
53±5 
(34 to 96) 
Respiration Rate 
(breaths per  
minute) 
Control 17 
(14 to 22) 
16.5 
(13 to 19) 
15 






(9 to 20)  
12.5 
(12 to 17) 
12** 
(9 to 15)  
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 For buprenorphine maintained subjects Morphine 1 was initial 15.2 mg bolus of 
morphine sulphate followed by 8.3 mg/hr constant infusion for one hour. 
2
Morphine 2 
was 15.2 mg bolus of morphine sulphate followed by 16.5 mg constant infusion for one 
hour. For controls Morphine 1 was initial bolus of 2.2 mg morphine sulphate followed by 
1.2 mg/hr constant infusion for one hour. Morphine 2 was 4.95 bolus of morphine 
sulphate followed by constant infusion of 3.6 mg/hr for one hour. Data for the 
nociceptive responses are mean±SEM (range) and for respiration rates median (range). 
3
The results for the three buprenorphine dose groups are combined. 
4
ANOVA P values comparing baseline to Morphine 1 and Morphine 2.  
† P<0.05, †† P<0.01 buprenorphine versus control; * P<0.05, ** P<0.01 morphine 2 
versus control. 
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Table 2A. Plasma morphine concentrations (ng/ml) on morphine administration days in 12 
buprenorphine maintained and 10 healthy control subjects. 
 
 Morphine 1 Morphine 2 








70±8 (49 to 91) 175±15 (119 to 201) 
Buprenorphine Subjects 
9-15 mg/day 
60±4 (48 to 71) 129±9 (48 to 108) 
Buprenorphine Subjects 
16-22 mg/day 
57±4 (52 to 71) 109±8 (92 to 129) 
 
The infusion regimens for buprenorphine maintained subjects and healthy control subjects on 
Morphine 1 and Morphine 2 days are described in the methods. Data are mean±SEM (range). 
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Table 2B. Plasma buprenorphine concentrations (ng/ml) at baseline and on morphine 
administration days in 12 buprenorphine maintained subjects.   
 




(0.23 to 3.3) 
0.95±0.19 
(0.16 to 0.23) 
 
1.03±0.23 




(0.42 to 1.17) 
0.46±0.12 
(0.16 to 0.76) 
0.45±0.10 




(0.21 to 2.20) 
1.14±0.36 
(0.90 to 1.75) 
1.40±0.53 




(0.8 to 1.98) 
1.23±0.24 
(0.79 to 1.79) 
1.33±0.22 
(0.79 to1.87) 
The morphine infusion regimens on Morphine 1 and Morphine 2 days are described in 
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Table 2C. Plasma norbuprenorphine concentrations (ng/ml) at baseline and on morphine 
administration days in 12 buprenorphine maintained subjects.   
 
 












The morphine infusion regimens on Morphine 1 and Morphine 2 days are described in 
the methods. Data are mean±SEM (range). 
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Supplementary Table. Plasma concentrations of buprenorphine (A)  and 
norbuprenorphine (B)  in 12 buprenorphine maintained subjects on saline infusion days.   
A. Plasma buprenorphine (ng/ml) 
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B. Plasma Norbuprenorphine  (ng/ml) 
 










The infusion regimens are described in the methods. Data are mean±SEM (range).  
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Buprenorphine maintenance subjects are hyperalgesic and have no 
antinociceptive response to a very high morphine dose 
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Objective. Acute pain management in opioid dependent persons is complicated 
because of tolerance and opioid-induced-hyperalgesia. Very high doses of morphine 
are ineffective in overcoming opioid-induced-hyperalgesia and providing 
antinociception to methadone maintained patients in an experimental setting. 
Whether the same occurs in buprenorphine maintained subjects is unknown. 
 
Design. Randomised double blind placebo controlled. Subjects were tested on two 
occasions, at least five days apart; once with intravenous morphine and once with 





Subjects. Twelve buprenorphine maintained subjects: once daily sublingual dose 
(range 2-22 mg); no dose change for 1.5-12 months. Ten healthy controls.  
 
Methods. Intravenous morphine bolus and infusions administered over 2 hours to 
achieve two separate pseudo-steady state plasma concentrations one hour apart. 
Pain tolerance assessed by application of nociceptive stimuli (cold pressor (seconds) 
and electrical stimulation (volts)). Ten blood samples collected for assay of plasma 
morphine, buprenorphine and norbuprenorphine concentrations until 3 hours after 
the end of last infusion; pain tolerance and respiration rate measured to coincide with 
blood sampling times. 
 
Results. Cold pressor responses (seconds): baseline: control 34±6 versus 
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buprenorphine 17±2 (P=0.009); morphine infusion-end: control 52±11(P=0.04), 
buprenorphine 17±2 (P>0.5); electrical stimulation responses (volts): baseline: 
control 65±6 versus buprenorphine 53±5 (P=0.13); infusion-end: control 74±5 
(P=0.007), buprenorphine 53±5 (P>0.98). Respiratory rate (breaths per minute): 
baseline: control 17 versus buprenorphine 14 (P=0.03); infusion-end: control 15 
(P=0.09), buprenorphine 12 (P<0.01). Infusion-end plasma morphine concentrations 
(ng/mL): control 23±1, buprenorphine 136±10. 
 
Conclusions. Buprenorphine subjects, compared with controls, were: hyperalgesic 
(cold pressor test); did not experience antinociception, despite high plasma morphine 
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The prevalence of opioid dependence is growing worldwide. Dependence has 
traditionally been the result of illicit opioid abuse. However, it is increasingly 
associated with legally prescribed long-term use of opioids for the management of 
chronic pain [1]. Between 28 and 38.5 million people abuse opioids worldwide. In 
2015, 2 million had a substance use disorder involving prescription pain relievers 
and 591,000 had a substance use disorder involving heroin [2]. Approximately 1% of 
the Australian population is opioid dependent and half of these are in opioid 
substitution treatment (OST) programs [3]. Of these, two-thirds receive methadone 
and one third buprenorphine (alone or with naloxone) but this difference is declining. 
 
The management of acute pain in opioid dependent patients is complicated 
because of two major factors: tolerance, which can generally be overcome by dose 
increase but may be compromised by adverse effects, and the under recognized 
phenomenon of opioid-induced-hyperalgesia (OIH) characterized as paradoxical 
pain sensitization [4] which cannot be overcome by dose increase. Although there 
are no formal guidelines for the clinician, Macintyre et al [5] and Huxtable et al [6] 
advise, that in the clinical setting, the daily OST dose should be maintained and 
additional opioid used for acute pain management, titrated until satisfactory 
analgesia is achieved or an adverse effect (e.g. sedation or respiratory depression) 
occurs. Such an approach requires stringent observation such as admission to 
hospital. 
 
Opioid-induced hyperalgesia occurs in opioid (e.g. heroin) addicted subjects prior to 
entry into methadone and buprenorphine treatments [7], chronic non-cancer pain 
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patients [8], and slow release morphine, methadone and buprenorphine maintained 
subjects [9, 10, 11, 12]. Clinically used and very high doses of morphine are 
ineffective in overcoming OIH and providing antinociception to methadone 
maintained patients [11, 13] in an experimental setting. Whether the same occurs in 
buprenorphine maintained subjects is unknown. 
 
Buprenorphine, a semi-synthetic 4,5-epoxymorphinan opioid shows partial agonist 
properties for some responses at the mu opioid receptor and variable effects at 
the kappa and delta receptors [14]. Its major metabolite norbuprenorphine is also 
active [15], although there is conjecture whether it crosses the blood-brain barrier 
[16]. Opioid agonists such as morphine, over plasma concentration ranges that 
produce dose-related increases in analgesia, also produce concentration-
dependent respiratory depression without any plateau in healthy human 
volunteers [17]. In contrast, buprenorphine shows dose-dependent increases in 
analgesia with a limited extent of respiratory depression [17, 18]. As a partial 
agonist, under appropriate conditions, buprenorphine may act as an agonist or 
antagonist at opioid receptors [19] and has shown antihyperalgesic effects in 
healthy subjects using a model of intradermal electric stimulation [20]. Therefore, 
buprenorphine may be unique in its ability to treat acute pain and possibly 
attenuate OIH. 
 
Previously we showed that methadone maintained subjects on doses of 2-120 mg 
per day, under identical experimental conditions that will be described in this study, 
experienced no antinociception with 55 mg of intravenous morphine but showed a 
significant reduction in respiratory rate [13]. To date, no studies have examined the 
effect of different daily buprenorphine doses on the antinociceptive and respiratory 
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responses to morphine. 
 
The aims of the study in buprenorphine maintained subjects were to: 1. Confirm the 
presence of OIH; 2. Ascertain whether very high intravenous morphine doses 
produce antinociceptive and respiratory depression effects and 3. Determine any 
relationship between buprenorphine dose and these effects. Our hypothesis is that 
buprenorphine maintained subjects are hyperalgesic and, that in contrast to 





The Research Ethics Committee of the Royal Adelaide Hospital, Adelaide, South 
Australia, Australia (RAH Protocol no: 010222) and the Institutional Review Board, 
Friends Research Institute, Los Angeles, California, USA (FRI IRB no: 00-03-057-
02) approved the study. Both bodies adhere to the ethical standards set by the 
Helsinki Declaration (2008). The study was supported by National Institutes of Drug 
Abuse (NIDA) grant R01 DA 13706-02. This study was not registered on 
clinicaltrials.gov as this study was carried out before the requirement for 
registration. Subjects provided written informed consent, were paid for their 
involvement in the study and were free to withdraw at any time. 
 
Subjects 
Twelve pain-free buprenorphine maintained subjects comprising 7 men and 5 
women with ages between 24 and 42 years (mean 35 years) were recruited. Their 
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weights ranged between 49 and 97 kg (mean 71 kg). They had been receiving 
sublingual buprenorphine (Subutex ® Reckitt Benckiser, West Ryde, New South 
Wales, Australia) for between 1.5 and 12 months (mean 4 months) with no dose 
change. They had been enrolled in a buprenorphine maintenance program for a 
period ranging between 2 and 22 months with a mean of 10 months. The group 
was stratified according to prescribed and efficacious maintenance dose, with four 
subjects in each of the dose ranges of 2 to 8 mg, 9 to 15 mg and 16 to 22 mg per 
day. Subjects were recruited if they self-reported intravenous heroin use at least 
once in the previous m nth. It was considered more ethical to administer morphine 
to individuals who continued to use illicit heroin, rather than to those who used no 
opioids, apart from their prescribed buprenorphine. Ten healthy control subjects (5 
men and 5 women; aged between 21 and 41(mean 31) years); weight 59 and 102 
(mean 80) kg) were selected. These subjects were not taking any prescribed 




Exclusion criteria for all subjects included pregnancy or lactation, use of 
antiretroviral drugs, significant medical or psychiatric illness that required ongoing 
treatment (except opioid addiction for buprenorphine subjects), daily alcohol 
consumption exceeding 40 g for men and 20 g for women, severe liver impairment 
(serum aspartate aminotransferase and alanine aminotransferase concentrations 
greater than 3 times the upper limit of normal range and albumin concentrations 
less than 33 grams per litre) or haemoglobin counts outside the normal range. 
Healthy control subjects were excluded if they had any personal or family history of 
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The study utilized a double blind placebo controlled design with four groups of 
subjects (healthy controls, once daily buprenorphine dose of 2 to 8, 9 to 15 and, 
16 to 22 mg). Subjects were tested on two occasions, at least five days apart; 
once with morphine and once with saline. The order of administration was 
randomised. Buprenorphine subjects were tested at about the time of putative 
trough plasma concentrations of buprenorphine (approximately 20 hours after 
the previous buprenorphine dose). 
Procedure 
Subjects were asked not to use any analgesics or illicit substances for twenty-four 
hours prior to testing. A urine sample was collected on each study day for the 
detection of opioids, benzodiazepines, sympathomimetic amines, cannabinoids and 
barbiturates. Analysis of these samples confirmed that control subjects had not taken 
any of these psychoactive substances. Subjects were excluded from the study if they 
presented on study or screening days showing any signs of intoxication from any 
substance. 
 
Testing was conducted under constant ambient temperature (24LC) and constant 
illumination (70 lux). Each session commenced at approximately 8 am and lasted 8 
hours. Two indwelling catheters (Insyte Autoguard, Becton Dickenson, Sandy, Utah, 
USA) were inserted into peripheral veins on opposite arms. The catheter in the 
dominant arm served for drug infusion; the catheter in the non-dominant arm for 
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blood sampling. On each testing day, saline was infused at 2 ml/min for 30 min prior 
to morphine or saline administration for familiarisation. 
 
Morphine administration 
Morphine sulphate (David Bull Laboratories, Melbourne, Australia) infusions of 1 
mg/ml were administered intravenously in two sixty-minute stages to achieve two 
consecutive target pseudo-steady-state plasma concentrations [11] using a 
syringe driver infusion pump (3100 Graseby Syringe Pump, Watford, Hertfordshire, 
UK). Buprenorphine subjects received an initial bolus of 15.2 mg of morphine 
sulphate followed by a constant infusion of 8.3 mg/hr for one hour to achieve a 
target pseudo steady-state plasma concentration of 80 ng/ml (Morphine 1). They 
were then administered an additional bolus of 15.2 mg of morphine sulphate 
followed by a constant infusion of 16.5 mg/hr for one hour to achieve the second 
target pseudo steady-state plasma concentration of 180 ng/ml (Morphine 2). The 
prescribed buprenorphine dose was administered 1 hour after infusions ceased. 
Control subjects were administered an initial bolus of 2.2 mg morphine sulphate 
followed by a constant infusion of 1.2 mg/hr for one hour to achieve a target 
pseudo steady-state plasma concentration of 11 ng/ml (Morphine 1). They were 
then administered 4.95 mg of morphine sulphate followed by a constant infusion of 
3.6 mg/hr to achieve the second target pseudo steady-state plasma concentration 
of 33 ng/ml (Morphine 2) [11]. 
 
Blood sampling and assessment times  
Seven millilitre blood samples were taken at the following times: prior to the thirty 
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minute saline familiarisation infusion, ten minutes prior to end of this infusion 
(designated as baseline) and ten minutes prior to the end of each of the two 
morphine or placebo saline infusions. Further blood samples were taken at 0.25, 
0.5, 0.75, 1.0, 2.0, and 3 hours after the end of the last infusion. The blood samples 
were centrifuged immediately and the plasma stored at –20 LC until assay. 
Respiration rate was measured and nociceptive tests (see below) were 
administered immediately after the collection of each blood sample except at 0.25, 
0.50 and 0.75 hours after the last infusion. 
 
Nociceptive tests, physiological responses and safety monitoring 
Two nociceptive tests were administered: the cold pressor using the non-dominant 
arm, and electrical stimulation using the earlobe. These tests have been described 
previously [10]. Cold pressor involves the immersion of the non-dominant arm in 
0.5–1.5 LC water and the response metric is seconds. Electrical stimulation 
involves the transmission of an electrical pulse through the earlobe and is 
measured in volts. One nociceptive marker was used which was pain tolerance, 
when the participant verbally indicated that they could no longer tolerate the pain 
and removed their arm from the water or requested that the electrical stimulation 
cease. 
 
Respiration rate was measured over one minute by observation without the 
subjects’ awareness. Safety was monitored and recorded throughout the study 
by means of continuous pulse oximetry, continuous ECG waveform, categorical 
nausea scale [21] and categorical sedation scale [22]. 
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Plasma opioid quantification 
The quantification of plasma buprenorphine and norbuprenorphine was by high 
performance liquid chromatography coupled to mass spectrometry as previously 
described [23]. The assay had a limit of quantification of 0.125 ng/ml for both 
analytes and all variability in accuracies and precision had coefficients of variation 
for buprenorphine and nor-buprenorphine of less than 15%. The quantification of 
plasma morphine was by high-performance liquid chromatography (HPLC) with 
coulometric detection as previously described [11]. The assay had a lower limit of 
quantification of 1 ng/ml and all variability in accuracies and precision had 
coefficients of variation below 7%. 
 
Data analysis 
Data are presented as mean ± SEM (with 95% confidence intervals (95% CI)). 
One-way ANOVA was used to compare outcome variables (cold pressor 
tolerance, electrical stimulation tolerance, respiration rate) between the 
buprenorphine dose groups. One-way ANOVA was used to compare each 
outcome variable across treatments for the buprenorphine dose groups, combined 
buprenorphine subjects and the control subjects with 95% CI of differences. 
Unpaired samples t-tests were used to compare baseline values between the 
combined buprenorphine subjects and the control subjects. The Pearson product-
moment correlation coefficient (Pearson’s r) was used to measure the linear 
correlation between individual buprenorphine daily doses and plasma morphine 
concentrations. Bonferroni’s and Dunnet’s tests were used for post-hoc analyses 
as appropriate. Data for both studies were analysed using GraphPad Prism 4.2 for 
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Windows, GraphPad Software, San Diego, California, USA and P<0.05 was 




There were no significant differences (P>0.45) in pain tolerance responses between 
the three buprenorphine dose groups from baseline to morphine infusion 1 or 
morphine infusion 2. Hence, the data from the groups were combined.  
 
Cold pressor responses 
Pain tolerance responses at baseline and morphine infusion 2 for control subjects 
and the buprenorphine subjects are shown in Figure 1 (upper panel) and absolute 
values and ranges for all treatments in Table 1. Pain tolerance values for the 
buprenorphine subjects remained unchanged between baseline and the two 
morphine infusions. Pain tolerance values for the buprenorphine subjects were 
significantly lower than for control subjects at baseline (ANOVA P=0.009; 95% CI -
5 to -30). Within group comparisons revealed that pain tolerance values for control 
subjects increased significantly (P=0.04) from baseline to morphine infusion 2 
(P<0.05; 95% CI 2 to 34), but not baseline to morphine infusion 1 (P>0.05; 95% CI 
-12 to 20).  
 
Electrical stimulation responses 
Pain tolerance responses at baseline and morphine infusion 2 for control subjects 
and the buprenorphine subjects are shown in Figure 1 (middle panel) and absolute 
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values with ranges given in Table 1. Pain tolerance values for the buprenorphine 
subjects were not significantly different to controls (ANOVA P=0.13) at baseline. 
Within-group comparisons revealed that pain tolerance values for control subjects 
increased significantly (P=0.007) from baseline to morphine infusion 2 (P<0.01; 
95% CI 3 to 16), but not baseline to morphine infusion 1 (P>0.05; 95% CI -2.8 to 
10). There was no significant change (P=0.98) in pain tolerance values for 
combined buprenorphine subjects from baseline to morphine infusion 1 or 
morphine infusion 2.  
 
Respiration rates 
Respiration rates (breaths per minute) relative to baseline and morphine infusion 2 
are shown in Figure 1 (lower panel) and absolute values with ranges in Table 1. 
Respiration rates for the buprenorphine subjects were significantly lower than for 
control subjects at baseline (ANOVA P=0.03; 95% CI -0.25 to -4.9). Within group 
comparisons revealed that the respiration rates for control subjects did not decrease 
significantly (P=0.09) from baseline to morphine infusion 1 or morphine infusion 2. 
Respiration rates for the buprenorphine subjects decreased significantly (ANOVA 
P=0.006) from baseline to morphine infusion 2 (P<0.01; 95% CI -0.9 to -4.4) but not 
morphine infusion 1 (P>0.05; 95% CI -2.8 to 10). 
 
Buprenorphine dose group comparisons demonstrated significant changes in 
respiration rates as follows. Group 2-8 mg daily: (ANOVA P=0.024) from baseline to 
morphine infusion 1 (P<0.05; 95% CI -0.56 to -7.4) and baseline to morphine 
infusion 2 (P<0.05; 95% CI -0.56 to - 7.4); group 9-15 mg daily: (ANOVA P=0.004) 
between baseline and morphine infusion 2 (P<0.01; 95% CI –1.48 to-5.52), but not 
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morphine infusion 1 (P>0.05; 95% CI -2.02 to 2.02); group 16 to 22 mg daily: 
(ANOVA P=0.016) between both baseline and morphine infusion 1 (P<0.05; 95% CI 
-0.72 to -4.28) and baseline and morphine infusion 2 (P<0.05; 95% CI -0.22 to -
3.78). There were no significant differences in respiration rate between the groups 
at baseline (P=0.90) or morphine infusion 2 (P=0.67). The lowest recorded 
respiration rates were ten breaths per minute in the control group and nine breaths 
per minute in the buprenorphine subjects. 
 
Adverse events 
There were no serious adverse events. Buprenorphine subjects did not experience 
nausea or vomiting, but seven control subjects required one dose of intramuscular 
metoclopramide hydrochloride 10 mg (Pfizer, Perth, Australia) with good effect for 
mild vomiting. 
 
Plasma morphine, buprenorphine and norbuprenorphine concentrations  
Pseudo steady-state plasma morphine concentrations for morphine 1 and 2 
infusions are shown in Table 2A. Target pseudo steady-state plasma morphine 
concentration for the buprenorphine recipients were 80 ng/ml (Morphine 1) and 180 
mg/ml (Morphine 2). Target pseudo steady-state plasma concentration for control 
subjects were 11 ng/ml (Morphine 1) and 33 mg/ml (Morphine 2). Pseudo state 
plasma morphine concentrations were lower than the desired target in both groups 
at morphine 1 and 2. Plasma morphine concentrations are also shown for the 
individual daily buprenorphine dose groups 2-8, 9-15 and 16-22 mg/day. There was 
no significant correlation (p=0.08) between individual buprenorphine doses and 
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plasma morphine concentrations at morphine infusion 1. However, there was a 
significant inverse relationship between individual buprenorphine doses and plasma 
morphine concentrations at morphine infusion 2 (Pearson’s r =-0.74, p=0.006; slope 
95% CI - 0.92 to -0.28).   
 
There were no significant differences between combined mean plasma 
buprenorphine concentrations (Table 2B), or for the three dose groups, at baseline 
(P=0.64), morphine infusion 1 (P=0.71) or morphine infusion 2 (P=0.51).  Likewise, 
there were no significant differences between combined mean plasma 
norbuprenorphine concentrations (Table 2C), or for the three dose groups, at 
baseline, morphine infusion 1 or morphine infusion 2. At baseline on the saline 
administration day, plasma buprenorphine and norbuprenorphine concentrations 
were correlated to the buprenorphine dose (r2=0.36 and 0.58, respectively; 




To our knowledge, this is the first study to have examined the effect of added 
morphine to buprenorphine OST subjects who were pain-free at the time of study, 
using an experiment pain model. Buprenorphine subjects were hyperalgesic in the 
cold pressor test in comparison with controls. Very high doses of morphine (55 mg) 
produced high plasma concentrations (92 to 201 ng/ml) that failed to provide 
antinociception in either the electrical stimulation or cold pressor tests, irrespective 
of maintenance buprenorphine dose. In contrast, in control subjects, considerably 
lower morphine doses (12 mg), achieving much lower concentrations (19 to 32 
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ng/ml), provided antinociception in both tests. 
 
Our choice of using the cold pressor response to study opioid induced- 
hyperalgesia has been validated by others. Compton et al [13] examined 
hyperalgesia in opioid dependent subjects and found that these subjects, prior to 
induction and following stabilisation on either methadone or buprenorphine, were 
similarly hyperalgesic in the cold pressor test and did not exhibit hyperalgesia in the 
electrical stimulation test. Krishnan et al [12] compared the detection of 
hyperalgesia in opioid-substitution subjects maintained either on methadone or 
buprenorphine and healthy controls using the following pain stimuli: cold pain, 
electrical stimulation, mechanical pressure, and ischemic pain. They found that cold 
pain was the most suitable of the methods tested to detect opioid-induced 
hyperalgesia. 
 
While the buprenorphine maintained subjects were tolerant to the antinociceptive 
effects of the high doses of morphine and plasma co centrations to which they 
were exposed, complete cross-tolerance to the respiratory depressant effects of 
morphine did not occur. Respiration rates dropped significantly across all dose 
groups, but by a limited amount (approximately 1.5 breaths per minute), which may 
not be clinically significant. In healthy volunteer subjects who received a single 
intravenous dose (0.2 mg/kg) of morphine, over a plasma concentration range 
(approximating 3-13 ng/mL) that produced a systematic increase in analgesia, 
morphine produced significant respiratory depression [24]. In contrast, in healthy 
adult volunteers who had experience with opioids but who were not physically 
dependent on opioids, Walsh and co-workers [18] demonstrated that respiratory 
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depression increased with single buprenorphine single doses over a range of 1 to 4 
mg (approximately 4 breaths per minute decrease), but that this dose effect began 
to plateau at higher doses, with no difference between a 16 and 32 mg dose. In the 
present study, with subjects chronically maintained on buprenorphine, high doses 
of added morphine had a limited respiratory depressant effect at all buprenorphine 
doses. It is, however, possible that higher doses of morphine might produce 
respiratory depression if such doses are needed to achieve anti-nociception, given 
that the lowest respiratory rate recorded was nine breaths per minute. Macintyre et 
al [25] showed increased sedation score (a surrogate for respiratory depression) in 
buprenorphine-maintained patients who received higher doses of morphine 
equivalents following surgery than in this study.  
 
Hyperalgesia is likely to be present, to a lesser or greater degree, in opioid 
recipients for whatever indication. Non-cancer pain patients, maintained on either 
methadone or slow release oral morphine for the treatment of that pain, were 
shown to exhibit hyperalgesia in the cold pressor test [8], similar to that seen in 
methadone [13] and buprenorphine subjects (this study) in opioid substitution 
programs. Chakrabarti et al [26] (2010) found that people with a greater reported 
experience of pain prior to induction onto buprenorphine maintenance required 
greater daily doses. The present study found that there was no difference in the 
degree of hyperalgesia experienced at baseline between the three dose ranges. 
There was also no difference between the three dose ranges in terms of cross-
tolerance to the antinociceptive effects of very high dose morphine. 
 
The most widely used drugs in opioid substitution programmes worldwide are 
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methadone and buprenorphine, with the latter gaining increasing prominence. 
Methadone maintained subjects were examined under conditions identical [13] to 
those for the buprenorphine subjects in this study. The cold pressor test at 
baseline revealed that the combined methadone subjects were similarly 
hyperalgesic to the combined buprenorphine subjects. Furthermore, both groups 
were cross-tolerant to the antinociceptive effects of very high plasma morphine 
concentrations and both groups experienced similar decreases in respiration rate 
with the addition of very high plasma morphine concentrations. While 
buprenorphine has been used increasingly across the world because of its 
purported limited effect on respiratory depression and greater safety profile than 
other opioids such as morphine and methadone [17, 27, 28], our findings suggest 
that supplementary opioids for the management of pain in subjects in opioid 
substitution programs should be added cautiously under adequate supervision to 
avoid clinically significant respiratory depression. 
 
Koppert et al [20], in a mechanical hyperalgesia model found that acutely, 
buprenorphine had a pronounced antihyperalgesic effect and suggested this may 
have clinical advantages in the management of chronic pain. In observational 
studies of chronic pain patients who were switched from high dose full opioid 
agonists to sublingual buprenorphine, [29, 30], the switch resulted in meaningful 
reduction in pain scores. Buprenorphine was more effective than full opioid 
agonists. The authors postulated that these findings may have resulted from 
buprenorphine’s antihyperalgesic action [29]. However, Ravn and coworkers [31], 
using a multimodal testing technique, could not demonstrate any significant 
differences between morphine and buprenorphine in the profiles of 
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antihyperalgesia and analgesia in healthy volunteers. The present study shows 
that buprenorphine, a partial mu opioid receptor agonist and kappa receptor 
antagonist, when used as a maintenance agent, produces similar respiratory 
depression and hyperalgesia to methadone (a mu opioid receptor agonist) in 
opioid maintained subjects tested under the same experimental conditions [13]. 
These results suggest that, at the buprenorphine doses to which our subjects 
were exposed, antihyperalgesia could not be demonstrated with the cold pressor 
test. 
 
Macintyre and colleagues [25] examined retrospectively pain relief and opioid 
requirements in the first 24 hours after surgery in patients taking buprenorphine 
(dose range was similar to that in the present study) and methadone as OST. 
Outcomes in the two patient groups were similar. The post-operative 24-hour 
analgesia requirement, provided as patient controlled analgesia, was defined as 
morphine dose equivalents. Buprenorphine maintained patients required an 
average of 200 mg; methadone maintained patients required 221 mg. Pain 
scores were similar across both groups. Sedation scores of 2 or greater occurred 
in 22.7% and 24.1% of buprenorphine and methadone maintained patients 
respectively. This important clinical study was not designed to determine 
possible mechanisms for the outcomes. Our findings, in an experimental setting 
in OST pain-free patients, complement the findings of this clinical study: very 
large morphine equivalent doses result in insignificant analgesia and the 
development of respiratory depression, albeit small, given the relatively small 
(compared to the PCA doses in the clinical study) dose of morphine provided to 
our subjects. Our findings strongly suggest that hyperalgesia is a likely 
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mechanism for the findings of Macintyre and colleagues [25], in addition to 
tolerance. It is pertinent that buprenorphine and methadone maintained patients 
behaved almost identically, suggesting that buprenorphine had no 
antihyperalgesic properties.  
 
We measured plasma concentrations of morphine, buprenorphine and 
norbuprenorphine to more accurately assess the extent of exposure by the 
subject to these analytes, rather than relying simply on the given doses. While 
there were no significant differences between plasma buprenorphine 
concentrations for the three dose groups at baseline, there was considerable 
variability in the range of concentrations. Hyperalgesia occurred across the 
whole range of plasma concentrations. The lowest individual plasma 
buprenorphine concentration was 0.16 ng/ml (in the 2-8 mg/day dose group).  
 
Transdermal buprenorphine patches are increasingly used for the management 
of chronic pain. In Australia, they are available in various strengths, ranging from 
10-40 mg, which deliver 10 to 40 ug/h and are generally applied once a week, 
likely for prolonged periods. When 10 ug/h patches were administered to healthy 
volunteers once a week for 3 doses the average plasma concentrations were 
between 0.155 and 0.172 ng/ml across the 3 periods [32]; 20 ug/h patches 
administered to healthy volunteers as a single dose yielded mean maximum 
plateau plasma concentrations of about 0.25 ng/ml between 48 and 96 hours 
after application [33]; single applications of 35 and 70 ug/h patches yielded mean 
maximum plasma concentrations of 0.31 and 0.62 ng/ml respectively [34]. These 
values fall within the range of plasma concentrations described in the present 
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study that were associated with hyperalgesia. Thus, it would be reasonable to 
assume that some patients receiving buprenorphine for the management of 
chronic pain could be hyperalgesic. Kress [34] reviewed several trials/reports of 
the efficacy of transdermal buprenorphine (varying doses) in patients with cancer 
and noncancer pain with the minimum duration of observation of three months. In 
most of the studies, satisfactory pain relief occurred in at least 50% of subjects, 
suggesting that hyperalgesia may not be universal in patients suffering from pain 
rather than those who receive opioids as substitution treatment.  
 
There are several limitations to this study. The sample size is small and not driven 
by a formal power calculation. However, we based our population size on the 
results of Doverty et al [11], who showed highly significant differences in cold 
pressor tolerance between 16 healthy controls (n=16) and 16 methadone 
maintenance subjects.  Despite the smaller sample size in this study, significant 
differences were seen between buprenorphine recipients and the controls. Plasma 
buprenorphine concentrations were measured only at the putative peak. However, 
given the long half-life of buprenorphine and that the subjects would have been at 
steady state, we considered the sampling regimen justified.  
 
What might be the best strategy to improve pain relief in buprenorphine maintained 
patients who experience acute pain, such as following surgery or trauma? Reviews 
from Huxtable et al [6] and Schug et al [5] state that in the clinical setting, for the 
opioid maintained population, opioid dose should be increased until analgesia is 
achieved or sedation occurs and that the dose of the maintenance opioid should be 
continued without interruption [25]. The purpose of this study was to provide the 
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evidence for opioid dose escalation that would provide antinociception without 
respiratory depression in the buprenorphine maintained population. This study 
demonstrates that buprenorphine maintained subjects are hyperalgesic at baseline 
and that very high morphine doses result in limited respiratory depression, but not 
antinociception. There is a need to explore alternative strategies for providing acute 
pain relief in buprenorphine (and methadone) maintained patients. For example, 
Huxtable [6] and Schug et al [5] recommend that an adjuvant analgesic alone, or in 
combination with morphine, may overcome the limitations of cross-tolerance and 
side effects to provide pain management in the buprenorphine and methadone 
maintained population. 
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Figure 1. Cold pressor pain tolerance responses (upper panel), electrical stimulation 
pain tolerance responses (middle panel) and respiration rate (lower panel) mean (± 
SEM) pain in 10 healthy control and 12 buprenorphine subjects at baseline (B) and 
morphine infusion 2 (M2). † P<0.05; †† P<0.01 between groups; * P<0.05; ** P<0.01 
between treatments. Note: different morphine concentrations between buprenorphine 
and control subjects. 
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Objective. Acute pain management in opioid dependent persons is complicated 
because of tolerance and opioid-induced-hyperalgesia. Very high doses of morphine 
are ineffective in overcoming opioid-induced-hyperalgesia and providing 
antinociception to methadone maintained patients in an experimental setting. 
Whether the same occurs in buprenorphine maintained subjects is unknown. 
 
Design. Randomised double blind placebo controlled. Subjects were tested on two 
occasions, at least five days apart; once with intravenous morphine and once with 





Subjects. Twelve buprenorphine maintained subjects: once daily sublingual dose 
(range 2-22 mg); no dose change for 1.5-12 months. Ten healthy controls.  
 
Methods. Intravenous morphine bolus and infusions administered over 2 hours to 
achieve two separate pseudo-steady state plasma concentrations one hour apart. 
Pain tolerance assessed by application of nociceptive stimuli (cold pressor (seconds) 
and electrical stimulation (volts)). Ten blood samples collected for assay of plasma 
morphine, buprenorphine and norbuprenorphine concentrations until 3 hours after 
the end of last infusion; pain tolerance and respiration rate measured to coincide with 
blood sampling times. 
 
Results. Cold pressor responses (seconds): baseline: control 34±6 versus 
Page 66 of 92


































































buprenorphine 17±2 (P=0.009); morphine infusion-end: control 52±11(P=0.04), 
buprenorphine 17±2 (P>0.5); electrical stimulation responses (volts): baseline: 
control 65±6 versus buprenorphine 53±5 (P=0.13); infusion-end: control 74±5 
(P=0.007), buprenorphine 53±5 (P>0.98). Respiratory rate (breaths per minute): 
baseline: control 17 versus buprenorphine 14 (P=0.03); infusion-end: control 15 
(P=0.09), buprenorphine 12 (P<0.01). Infusion-end plasma morphine concentrations 
(ng/mL): control 23±1, buprenorphine 136±10. 
 
Conclusions. Buprenorphine subjects, compared with controls, were: hyperalgesic 
(cold pressor test); did not experience antinociception, despite high plasma morphine 
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The prevalence of opioid dependence is growing worldwide. Dependence has 
traditionally been the result of illicit opioid abuse. However, it is increasingly 
associated with legally prescribed long-term use of opioids for the management of 
chronic pain [1]. Between 28 and 38.5 million people abuse opioids worldwide. In 
2015, 2 million had a substance use disorder involving prescription pain relievers 
and 591,000 had a substance use disorder involving heroin [2]. Approximately 1% of 
the Australian population is opioid dependent and half of these are in opioid 
substitution treatment (OST) programs [3]. Of these, two-thirds receive methadone 
and one third buprenorphine (alone or with naloxone) but this difference is declining. 
 
The management of acute pain in opioid dependent patients is complicated 
because of two major factors: tolerance, which can generally be overcome by dose 
increase but may be compromised by adverse effects, and the under recognized 
phenomenon of opioid-induced-hyperalgesia (OIH) characterized as paradoxical 
pain sensitization [4] which cannot be overcome by dose increase. Although there 
are no formal guidelines for the clinician, Macintyre et al [5] and Huxtable et al [6] 
advise, that in the clinical setting, the daily OST dose should be maintained and 
additional opioid used for acute pain management, titrated until satisfactory 
analgesia is achieved or an adverse effect (e.g. sedation or respiratory depression) 
occurs. Such an approach requires stringent observation such as admission to 
hospital. 
 
Opioid-induced hyperalgesia occurs in opioid (e.g. heroin) addicted subjects prior to 
entry into methadone and buprenorphine treatments [7], chronic non-cancer pain 
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patients [8], and slow release morphine, methadone and buprenorphine maintained 
subjects [9, 10, 11, 12]. Clinically used and very high doses of morphine are 
ineffective in overcoming OIH and providing antinociception to methadone 
maintained patients [11, 13] in an experimental setting. Whether the same occurs in 
buprenorphine maintained subjects is unknown. 
 
Buprenorphine, a semi-synthetic 4,5-epoxymorphinan opioid shows partial agonist 
properties for some responses at the mu opioid receptor and variable effects at 
the kappa and delta receptors [14]. Its major metabolite norbuprenorphine is also 
active [15], although there is conjecture whether it crosses the blood-brain barrier 
[16]. Opioid agonists such as morphine, over plasma concentration ranges that 
produce dose-related increases in analgesia, also produce concentration-
dependent respiratory depression without any plateau in healthy human 
volunteers [17]. In contrast, buprenorphine shows dose-dependent increases in 
analgesia with a limited extent of respiratory depression [17, 18]. As a partial 
agonist, under appropriate conditions, buprenorphine may act as an agonist or 
antagonist at opioid receptors [19] and has shown antihyperalgesic effects in 
healthy subjects using a model of intradermal electric stimulation [20]. Therefore, 
buprenorphine may be unique in its ability to treat acute pain and possibly 
attenuate OIH. 
 
Previously we showed that methadone maintained subjects on doses of 2-120 mg 
per day, under identical experimental conditions that will be described in this study, 
experienced no antinociception with 55 mg of intravenous morphine but showed a 
significant reduction in respiratory rate [13]. To date, no studies have examined the 
effect of different daily buprenorphine doses on the antinociceptive and respiratory 
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responses to morphine. 
 
The aims of the study in buprenorphine maintained subjects were to: 1. Confirm the 
presence of OIH; 2. Ascertain whether very high intravenous morphine doses 
produce antinociceptive and respiratory depression effects and 3. Determine any 
relationship between buprenorphine dose and these effects. Our hypothesis is that 
buprenorphine maintained subjects are hyperalgesic and, that in contrast to 





The Research Ethics Committee of the Royal Adelaide Hospital, Adelaide, South 
Australia, Australia (RAH Protocol no: 010222) and the Institutional Review Board, 
Friends Research Institute, Los Angeles, California, USA (FRI IRB no: 00-03-057-
02) approved the study. Both bodies adhere to the ethical standards set by the 
Helsinki Declaration (2008). The study was supported by National Institutes of Drug 
Abuse (NIDA) grant R01 DA 13706-02. This study was not registered on 
clinicaltrials.gov as this study was carried out before the requirement for 
registration. Subjects provided written informed consent, were paid for their 
involvement in the study and were free to withdraw at any time. 
 
Subjects 
Twelve pain-free buprenorphine maintained subjects comprising 7 men and 5 
women with ages between 24 and 42 years (mean 35 years) were recruited. Their 
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weights ranged between 49 and 97 kg (mean 71 kg). They had been receiving 
sublingual buprenorphine (Subutex ® Reckitt Benckiser, West Ryde, New South 
Wales, Australia) for between 1.5 and 12 months (mean 4 months) with no dose 
change. They had been enrolled in a buprenorphine maintenance program for a 
period ranging between 2 and 22 months with a mean of 10 months. The group 
was stratified according to prescribed and efficacious maintenance dose, with four 
subjects in each of the dose ranges of 2 to 8 mg, 9 to 15 mg and 16 to 22 mg per 
day. Subjects were recruited if they self-reported intravenous heroin use at least 
once in the previous m nth. It was considered more ethical to administer morphine 
to individuals who continued to use illicit heroin, rather than to those who used no 
opioids, apart from their prescribed buprenorphine. Ten healthy control subjects (5 
men and 5 women; aged between 21 and 41(mean 31) years); weight 59 and 102 
(mean 80) kg) were selected. These subjects were not taking any prescribed 




Exclusion criteria for all subjects included pregnancy or lactation, use of 
antiretroviral drugs, significant medical or psychiatric illness that required ongoing 
treatment (except opioid addiction for buprenorphine subjects), daily alcohol 
consumption exceeding 40 g for men and 20 g for women, severe liver impairment 
(serum aspartate aminotransferase and alanine aminotransferase concentrations 
greater than 3 times the upper limit of normal range and albumin concentrations 
less than 33 grams per litre) or haemoglobin counts outside the normal range. 
Healthy control subjects were excluded if they had any personal or family history of 
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The study utilized a double blind placebo controlled design with four groups of 
subjects (healthy controls, once daily buprenorphine dose of 2 to 8, 9 to 15 and, 
16 to 22 mg). Subjects were tested on two occasions, at least five days apart; 
once with morphine and once with saline. The order of administration was 
randomised. Buprenorphine subjects were tested at about the time of putative 
trough plasma concentrations of buprenorphine (approximately 20 hours after 
the previous buprenorphine dose). 
Procedure 
Subjects were asked not to use any analgesics or illicit substances for twenty-four 
hours prior to testing. A urine sample was collected on each study day for the 
detection of opioids, benzodiazepines, sympathomimetic amines, cannabinoids and 
barbiturates. Analysis of these samples confirmed that control subjects had not taken 
any of these psychoactive substances. Subjects were excluded from the study if they 
presented on study or screening days showing any signs of intoxication from any 
substance. 
 
Testing was conducted under constant ambient temperature (24LC) and constant 
illumination (70 lux). Each session commenced at approximately 8 am and lasted 8 
hours. Two indwelling catheters (Insyte Autoguard, Becton Dickenson, Sandy, Utah, 
USA) were inserted into peripheral veins on opposite arms. The catheter in the 
dominant arm served for drug infusion; the catheter in the non-dominant arm for 
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blood sampling. On each testing day, saline was infused at 2 ml/min for 30 min prior 
to morphine or saline administration for familiarisation. 
 
Morphine administration 
Morphine sulphate (David Bull Laboratories, Melbourne, Australia) infusions of 1 
mg/ml were administered intravenously in two sixty-minute stages to achieve two 
consecutive target pseudo-steady-state plasma concentrations [11] using a 
syringe driver infusion pump (3100 Graseby Syringe Pump, Watford, Hertfordshire, 
UK). Buprenorphine subjects received an initial bolus of 15.2 mg of morphine 
sulphate followed by a constant infusion of 8.3 mg/hr for one hour to achieve a 
target pseudo steady-state plasma concentration of 80 ng/ml (Morphine 1). They 
were then administered an additional bolus of 15.2 mg of morphine sulphate 
followed by a constant infusion of 16.5 mg/hr for one hour to achieve the second 
target pseudo steady-state plasma concentration of 180 ng/ml (Morphine 2). The 
prescribed buprenorphine dose was administered 1 hour after infusions ceased. 
Control subjects were administered an initial bolus of 2.2 mg morphine sulphate 
followed by a constant infusion of 1.2 mg/hr for one hour to achieve a target 
pseudo steady-state plasma concentration of 11 ng/ml (Morphine 1). They were 
then administered 4.95 mg of morphine sulphate followed by a constant infusion of 
3.6 mg/hr to achieve the second target pseudo steady-state plasma concentration 
of 33 ng/ml (Morphine 2) [11]. 
 
Blood sampling and assessment times  
Seven millilitre blood samples were taken at the following times: prior to the thirty 
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minute saline familiarisation infusion, ten minutes prior to end of this infusion 
(designated as baseline) and ten minutes prior to the end of each of the two 
morphine or placebo saline infusions. Further blood samples were taken at 0.25, 
0.5, 0.75, 1.0, 2.0, and 3 hours after the end of the last infusion. The blood samples 
were centrifuged immediately and the plasma stored at –20 LC until assay. 
Respiration rate was measured and nociceptive tests (see below) were 
administered immediately after the collection of each blood sample except at 0.25, 
0.50 and 0.75 hours after the last infusion. 
 
Nociceptive tests, physiological responses and safety monitoring 
Two nociceptive tests were administered: the cold pressor using the non-dominant 
arm, and electrical stimulation using the earlobe. These tests have been described 
previously [10]. Cold pressor involves the immersion of the non-dominant arm in 
0.5–1.5 LC water and the response metric is seconds. Electrical stimulation 
involves the transmission of an electrical pulse through the earlobe and is 
measured in volts. One nociceptive marker was used which was pain tolerance, 
when the participant verbally indicated that they could no longer tolerate the pain 
and removed their arm from the water or requested that the electrical stimulation 
cease. 
 
Respiration rate was measured over one minute by observation without the 
subjects’ awareness. Safety was monitored and recorded throughout the study 
by means of continuous pulse oximetry, continuous ECG waveform, categorical 
nausea scale [21] and categorical sedation scale [22]. 
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Plasma opioid quantification 
The quantification of plasma buprenorphine and norbuprenorphine was by high 
performance liquid chromatography coupled to mass spectrometry as previously 
described [23]. The assay had a limit of quantification of 0.125 ng/ml for both 
analytes and all variability in accuracies and precision had coefficients of variation 
for buprenorphine and nor-buprenorphine of less than 15%. The quantification of 
plasma morphine was by high-performance liquid chromatography (HPLC) with 
coulometric detection as previously described [11]. The assay had a lower limit of 
quantification of 1 ng/ml and all variability in accuracies and precision had 
coefficients of variation below 7%. 
 
Data analysis 
Data are presented as mean ± SEM (with 95% confidence intervals (95% CI)).. 
One-way ANOVA was used to compare each outcome variable across treatments 
for the buprenorphine combined subjects and the control subjects with 95% CI of 
differences. Unpaired samples t-tests were used to compare baseline values 
between the combined buprenorphine subjects and the control subjects. The 
Pearson product-moment correlation coefficient (Pearson’s r) was used to 
measure the linear correlation between individual buprenorphine daily doses and 
plasma morphine concentrations. Bonferroni’s and Dunnet’s tests were used for 
post-hoc analyses as appropriate. Data for both studies were analysed using 
GraphPad Prism 4.2 for Windows, GraphPad Software, San Diego, California, 
USA and P<0.05 was considered significant.  
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There were no significant differences (P>0.45) in pain tolerance responses between 
the three buprenorphine dose groups from baseline to morphine infusion 1 or 
morphine infusion 2. Hence, the data from the groups were combined.  
 
Cold pressor responses 
Pain tolerance responses at baseline and morphine infusion 2 for control subjects 
and the buprenorphine subjects are shown in Figure 1 (upper panel) and absolute 
values and ranges for all treatments in Table 1. Pain tolerance values for the 
buprenorphine subjects remained unchanged between baseline and the two 
morphine infusions. Pain tolerance values for the buprenorphine subjects were 
significantly lower than for control subjects at baseline (ANOVA P=0.009; 95% CI -
5 to -30). Within group comparisons revealed that pain tolerance values for control 
subjects increased significantly (P=0.04) from baseline to morphine infusion 2 
(P<0.05; 95% CI 2 to 34), but not baseline to morphine infusion 1 (P>0.05; 95% CI 
-12 to 20).  
 
Electrical stimulation responses 
Pain tolerance responses at baseline and morphine infusion 2 for control subjects 
and the buprenorphine subjects are shown in Figure 1 (middle panel) and absolute 
values with ranges given in Table 1. Pain tolerance values for the buprenorphine 
subjects were not significantly different to controls (ANOVA P=0.13) at baseline. 
Within-group comparisons revealed that pain tolerance values for control subjects 
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increased significantly (P=0.007) from baseline to morphine infusion 2 (P<0.01; 
95% CI 3 to 16), but not baseline to morphine infusion 1 (P>0.05; 95% CI -2.8 to 
10). There was no significant change (P=0.98) in pain tolerance values for 
combined buprenorphine subjects from baseline to morphine infusion 1 or 
morphine infusion 2.  
 
Respiration rates 
Respiration rates (breaths per minute) relative to baseline and morphine infusion 2 
are shown in Figure 1 (lower panel) and absolute values with ranges in Table 1. 
Respiration rates for the buprenorphine subjects were significantly lower than for 
control subjects at baseline (ANOVA P=0.03; 95% CI -0.25 to -4.9). Within group 
comparisons revealed that the respiration rates for control subjects did not decrease 
significantly (P=0.09) from baseline to morphine infusion 1 or morphine infusion 2. 
Respiration rates for the buprenorphine subjects decreased significantly (ANOVA 
P=0.006) from baseline to morphine infusion 2 (P<0.01; 95% CI -0.9 to -4.4) but not 
morphine infusion 1 (P>0.05; 95% CI -2.8 to 10). 
 
Buprenorphine dose group comparisons demonstrated significant changes in 
respiration rates as follows. Group 2-8 mg daily: (ANOVA P=0.024) from baseline to 
morphine infusion 1 (P<0.05; 95% CI -0.56 to -7.4) and baseline to morphine 
infusion 2 (P<0.05; 95% CI -0.56 to - 7.4); group 9-15 mg daily: (ANOVA P=0.004) 
between baseline and morphine infusion 2 (P<0.01; 95% CI –1.48 to-5.52), but not 
morphine infusion 1 (P>0.05; 95% CI -2.02 to 2.02); group 16 to 22 mg daily: 
(ANOVA P=0.016) between both baseline and morphine infusion 1 (P<0.05; 95% CI 
-0.72 to -4.28) and baseline and morphine infusion 2 (P<0.05; 95% CI -0.22 to -
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3.78). There were no significant differences in respiration rate between the groups 
at baseline (P=0.90) or morphine infusion 2 (P=0.67). The lowest recorded 
respiration rates were ten breaths per minute in the control group and nine breaths 
per minute in the buprenorphine subjects. 
 
Adverse events 
There were no serious adverse events. Buprenorphine subjects did not experience 
nausea or vomiting, but seven control subjects required one dose of intramuscular 
metoclopramide hydrochloride 10 mg (Pfizer, Perth, Australia) with good effect for 
mild vomiting. 
 
Plasma morphine, buprenorphine and norbuprenorphine concentrations  
Pseudo steady-state plasma morphine concentrations for morphine 1 and 2 
infusions are shown in Table 2A. Target pseudo steady-state plasma morphine 
concentration for the buprenorphine recipients were 80 ng/ml (Morphine 1) and 180 
mg/ml (Morphine 2). Target pseudo steady-state plasma concentration for control 
subjects were 11 ng/ml (Morphine 1) and 33 mg/ml (Morphine 2). Pseudo state 
plasma morphine concentrations were lower than the desired target in both groups 
at morphine 1 and 2. Plasma morphine concentrations are also shown for the 
individual daily buprenorphine dose groups 2-8, 9-15 and 16-22 mg/day. There was 
no significant correlation (p=0.08) between individual buprenorphine doses and 
plasma morphine concentrations at morphine infusion 1. However, there was a 
significant inverse relationship between individual buprenorphine doses and plasma 
morphine concentrations at morphine infusion 2 (Pearson’s r =-0.74, p=0.006; slope 
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95% CI - 0.92 to -0.28).   
 
There were no significant differences between combined mean plasma 
buprenorphine concentrations (Table 2B), or for the three dose groups, at baseline 
(P=0.64), morphine infusion 1 (P=0.71) or morphine infusion 2 (P=0.51).  Likewise, 
there were no significant differences between combined mean plasma 
norbuprenorphine concentrations (Table 2C), or for the three dose groups, at 
baseline, morphine infusion 1 or morphine infusion 2. At baseline on the saline 
administration day, plasma buprenorphine and norbuprenorphine concentrations 
were correlated to the buprenorphine dose (r2=0.36 and 0.58, respectively; 




To our knowledge, this is the first study to have examined the effect of added 
morphine to buprenorphine OST subjects who were pain-free at the time of study, 
using an experiment pain model. Buprenorphine subjects were hyperalgesic in the 
cold pressor test in comparison with controls. Very high doses of morphine (55 mg) 
produced high plasma concentrations (92 to 201 ng/ml) that failed to provide 
antinociception in either the electrical stimulation or cold pressor tests, irrespective 
of maintenance buprenorphine dose. In contrast, in control subjects, considerably 
lower morphine doses (12 mg), achieving much lower concentrations (19 to 32 
ng/ml), provided antinociception in both tests. 
 
Our choice of using the cold pressor response to study opioid induced- 
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hyperalgesia has been validated by others. Compton et al [13] examined 
hyperalgesia in opioid dependent subjects and found that these subjects, prior to 
induction and following stabilisation on either methadone or buprenorphine, were 
similarly hyperalgesic in the cold pressor test and did not exhibit hyperalgesia in the 
electrical stimulation test. Krishnan et al [12] compared the detection of 
hyperalgesia in opioid-substitution subjects maintained either on methadone or 
buprenorphine and healthy controls using the following pain stimuli: cold pain, 
electrical stimulation, mechanical pressure, and ischemic pain. They found that cold 
pain was the most suitable of the methods tested to detect opioid-induced 
hyperalgesia. 
 
While the buprenorphine maintained subjects were tolerant to the antinociceptive 
effects of the high doses of morphine and plasma concentrations to which they 
were exposed, complete cross-tolerance to the respiratory depressant effects of 
morphine did not occur. Respiration rates dropped significantly across all dose 
groups, but by a limited amount (approximately 1.5 breaths per minute), which may 
not be clinically significant. In healthy volunteer subjects who received a single 
intravenous dose (0.2 mg/kg) of morphine, over a plasma concentration range 
(approximating 3-13 ng/mL) that produced a systematic increase in analgesia, 
morphine produced significant respiratory depression [24]. In contrast, in healthy 
adult volunteers who had experience with opioids but who were not physically 
dependent on opioids, Walsh and co-workers [18] demonstrated that respiratory 
depression increased with single buprenorphine single doses over a range of 1 to 4 
mg (approximately 4 breaths per minute decrease), but that this dose effect began 
to plateau at higher doses, with no difference between a 16 and 32 mg dose. In the 
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present study, with subjects chronically maintained on buprenorphine, high doses 
of added morphine had a limited respiratory depressant effect at all buprenorphine 
doses. It is, however, possible that higher doses of morphine might produce 
respiratory depression if such doses are needed to achieve anti-nociception, given 
that the lowest respiratory rate recorded was nine breaths per minute. Macintyre et 
al [25] showed increased sedation score (a surrogate for respiratory depression) in 
buprenorphine-maintained patients who received higher doses of morphine 
equivalents following surgery than in this study.  
 
Hyperalgesia is likely to be present, to a lesser or greater degree, in opioid 
recipients for whatever indication. Non-cancer pain patients, maintained on either 
methadone or slow release oral morphine for the treatment of that pain, were 
shown to exhibit hyperalgesia in the cold pressor test [8], similar to that seen in 
methadone [13] and buprenorphine subjects (this study) in opioid substitution 
programs. Chakrabarti et al [26] (2010) found that people with a greater reported 
experience of pain prior to induction onto buprenorphine maintenance required 
greater daily doses. The present study found that there was no difference in the 
degree of hyperalgesia experienced at baseline between the three dose ranges. 
There was also no difference between the three dose ranges in terms of cross-
tolerance to the antinociceptive effects of very high dose morphine. 
 
The most widely used drugs in opioid substitution programmes worldwide are 
methadone and buprenorphine, with the latter gaining increasing prominence. 
Methadone maintained subjects were examined under conditions identical [13] to 
those for the buprenorphine subjects in this study. The cold pressor test at 
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baseline revealed that the combined methadone subjects were similarly 
hyperalgesic to the combined buprenorphine subjects. Furthermore, both groups 
were cross-tolerant to the antinociceptive effects of very high plasma morphine 
concentrations and both groups experienced similar decreases in respiration rate 
with the addition of very high plasma morphine concentrations. While 
buprenorphine has been used increasingly across the world because of its 
purported limited effect on respiratory depression and greater safety profile than 
other opioids such as morphine and methadone [17, 27, 28], our findings suggest 
that supplementary opi ids for the management of pain in subjects in opioid 
substitution programs should be added cautiously under adequate supervision to 
avoid clinically significant respiratory depression. 
 
Koppert et al [20], in a mechanical hyperalgesia model found that acutely, 
buprenorphine had a pronounced antihyperalgesic effect and suggested this may 
have clinical advantages in the management of chronic pain. In observational 
studies of chronic pain patients who were switched from high dose full opioid 
agonists to sublingual buprenorphine, [29, 30], the switch resulted in meaningful 
reduction in pain scores. Buprenorphine was more effective than full opioid 
agonists. The authors postulated that these findings may have resulted from 
buprenorphine’s antihyperalgesic action [29]. However, Ravn and coworkers [31], 
using a multimodal testing technique, could not demonstrate any significant 
differences between morphine and buprenorphine in the profiles of 
antihyperalgesia and analgesia in healthy volunteers. The present study shows 
that buprenorphine, a partial mu opioid receptor agonist and kappa receptor 
antagonist, when used as a maintenance agent, produces similar respiratory 
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depression and hyperalgesia to methadone (a mu opioid receptor agonist) in 
opioid maintained subjects tested under the same experimental conditions [13]. 
These results suggest that, at the buprenorphine doses to which our subjects 
were exposed, antihyperalgesia could not be demonstrated with the cold pressor 
test. 
 
Macintyre and colleagues [25] examined retrospectively pain relief and opioid 
requirements in the first 24 hours after surgery in patients taking buprenorphine 
(dose range was similar to that in the present study) and methadone as OST. 
Outcomes in the two patient groups were similar. The post-operative 24-hour 
analgesia requirement, provided as patient controlled analgesia, was defined as 
morphine dose equivalents. Buprenorphine maintained patients required an 
average of 200 mg; methadone maintained patients required 221 mg. Pain 
scores were similar across both groups. Sedation scores of 2 or greater occurred 
in 22.7% and 24.1% of buprenorphine and methadone maintained patients 
respectively. This important clinical study was not designed to determine 
possible mechanisms for the outcomes. Our findings, in an experimental setting 
in OST pain-free patients, complement the findings of this clinical study: very 
large morphine equivalent doses result in insignificant analgesia and the 
development of respiratory depression, albeit small, given the relatively small 
(compared to the PCA doses in the clinical study) dose of morphine provided to 
our subjects. Our findings strongly suggest that hyperalgesia is a likely 
mechanism for the findings of Macintyre and colleagues [25], in addition to 
tolerance. It is pertinent that buprenorphine and methadone maintained patients 
behaved almost identically, suggesting that buprenorphine had no 
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antihyperalgesic properties.  
 
We measured plasma concentrations of morphine, buprenorphine and 
norbuprenorphine to more accurately assess the extent of exposure by the 
subject to these analytes, rather than relying simply on the given doses. While 
there were no significant differences between plasma buprenorphine 
concentrations for the three dose groups at baseline, there was considerable 
variability in the range of concentrations. Hyperalgesia occurred across the 
whole range of plasma concentrations. The lowest individual plasma 
buprenorphine concentration was 0.16 ng/ml (in the 2-8 mg/day dose group).  
 
Transdermal buprenorphine patches are increasingly used for the management 
of chronic pain. In Australia, they are available in various strengths, ranging from 
10-40 mg, which deliver 10 to 40 ug/h and are generally applied once a week, 
likely for prolonged periods. When 10 ug/h patches were administered to healthy 
volunteers once a week for 3 doses the average plasma concentrations were 
between 0.155 and 0.172 ng/ml across the 3 periods [32]; 20 ug/h patches 
administered to healthy volunteers as a single dose yielded mean maximum 
plateau plasma concentrations of about 0.25 ng/ml between 48 and 96 hours 
after application [33]; single applications of 35 and 70 ug/h patches yielded mean 
maximum plasma concentrations of 0.31 and 0.62 ng/ml respectively [34]. These 
values fall within the range of plasma concentrations described in the present 
study that were associated with hyperalgesia. Thus, it would be reasonable to 
assume that some patients receiving buprenorphine for the management of 
chronic pain could be hyperalgesic. Kress [34] reviewed several trials/reports of 
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the efficacy of transdermal buprenorphine (varying doses) in patients with cancer 
and noncancer pain with the minimum duration of observation of three months. In 
most of the studies, satisfactory pain relief occurred in at least 50% of subjects, 
suggesting that hyperalgesia may not be universal in patients suffering from pain 
rather than those who receive opioids as substitution treatment.  
 
There are several limitations to this study. The sample size is small and not driven 
by a formal power calculation. However, we based our population size on the 
results of Doverty et al [11], who showed highly significant differences in cold 
pressor tolerance between 16 healthy controls (n=16) and 16 methadone 
maintenance subjects.  Despite the smaller sample size in this study, significant 
differences were seen between buprenorphine recipients and the controls. Plasma 
buprenorphine concentrations were measured only at the putative peak. However, 
given the long half-life of buprenorphine and that the subjects would have been at 
steady state, we considered the sampling regimen justified.  
 
What might be the best strategy to improve pain relief in buprenorphine maintained 
patients who experience acute pain, such as following surgery or trauma? Reviews 
from Huxtable et al [6] and Schug et al [5] state that in the clinical setting, for the 
opioid maintained population, opioid dose should be increased until analgesia is 
achieved or sedation occurs and that the dose of the maintenance opioid should be 
continued without interruption [25]. The purpose of this study was to provide the 
evidence for opioid dose escalation that would provide antinociception without 
respiratory depression in the buprenorphine maintained population. This study 
demonstrates that buprenorphine maintained subjects are hyperalgesic at baseline 
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and that very high morphine doses result in limited respiratory depression, but not 
antinociception. There is a need to explore alternative strategies for providing acute 
pain relief in buprenorphine (and methadone) maintained patients. For example, 
Huxtable [6] and Schug et al [5] recommend that an adjuvant analgesic alone, or in 
combination with morphine, may overcome the limitations of cross-tolerance and 
side effects to provide pain management in the buprenorphine and methadone 
maintained population. 
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Figure 1. Cold pressor pain tolerance responses (upper panel), electrical stimulation 
pain tolerance responses (middle panel) and respiration rate (lower panel) mean (± 
SEM) pain in 10 healthy control and 12 buprenorphine subjects at baseline (B) and 
morphine infusion 2 (M2). † P<0.05; †† P<0.01 between groups; * P<0.05; ** P<0.01 
between treatments. Note: different morphine concentrations between buprenorphine 
and control subjects. 
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